#PORTABLE PNEUMATIC COMPRESSION DEVICE PORTABLE#

Only two control patients were diagnosed with a PE (0.23%), while one patient in the ASA alone group had DVT (0.07%). A total of 867 controls and 1,352 patients treated with ASA alone were identified. A posthoc power analysis was performed using a noninferiority margin of 0.25 (α = 0.05 power = 80%), which showed that our sample size was fully powered for noninferiority for our reported deep vein thrombosis (DVT) rates, but not for pulmonary embolism (PE) rates. All study patients received inpatient IPCDs and were maintained on 81-mg ASA BID for 28 days. Patients in cohort one received outpatient IPCDs for a period of 14 days (control), while those in cohort two did not (ASA alone). A retrospective review of 2,219 consecutive TKA cases was conducted, identifying patients with VTE, bleeding complications, infection, and mortality within 90 days postoperatively. The aim of this study is to determine if discontinued use of outpatient IPCDs is safe and does not increase the rate of VTE or any other related complications in patients following TKA.

#PORTABLE PNEUMATIC COMPRESSION DEVICE PORTABLE#

At our institution, both 81-mg aspirin (ASA) twice a day (BID) and portable IPCDs were previously prescribed to TKA patients at standard risk for VTE, but the IPCDs were discontinued and patients were treated with ASA alone going forward. Current VTE guidelines recommend pharmacologic agents with or without intermittent pneumatic compression devices (IPCDs). Venous thromboembolism (VTE) is a rare, but serious complication following total knee arthroplasty (TKA). Buy Article Permissions and Reprints Abstract

Portable pneumatic compression device